NO20071446L - Endotelin A reseptor (ETA)-antagonister i kombinasjon med fosfodiesterase 5-inhibitorer (PDE5) og anvendelser derav. - Google Patents

Endotelin A reseptor (ETA)-antagonister i kombinasjon med fosfodiesterase 5-inhibitorer (PDE5) og anvendelser derav.

Info

Publication number
NO20071446L
NO20071446L NO20071446A NO20071446A NO20071446L NO 20071446 L NO20071446 L NO 20071446L NO 20071446 A NO20071446 A NO 20071446A NO 20071446 A NO20071446 A NO 20071446A NO 20071446 L NO20071446 L NO 20071446L
Authority
NO
Norway
Prior art keywords
eta
pde5
endothelin
phosphodiesterase
receptor
Prior art date
Application number
NO20071446A
Other languages
English (en)
Inventor
Donald Keyser
Richard Dixon
Original Assignee
Encysive Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encysive Pharmaceuticals Inc filed Critical Encysive Pharmaceuticals Inc
Publication of NO20071446L publication Critical patent/NO20071446L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives generelt kombinasjonsterapier som omfatter en endotelin A-reseptor (ETA) antagonist og en fosfodiesterase 5-(PDE5) inhibitor, farmasøytiske blandinger som omfatter en ETA-antagonist og PDE5-inhibitor og fremgangsmåter for behandling av forskjellige lidelser, omfattende administrering av en ETA-antagonist og en PDE5-inhibitor. Kombinasjonsterapiene og de farmasøytiske blandingene er særlig egnet til behandlingen og/eller forebyggelsen av hjertelidelser som pulmonal arteriell hypertensjon (PAH).
NO20071446A 2004-08-26 2007-03-16 Endotelin A reseptor (ETA)-antagonister i kombinasjon med fosfodiesterase 5-inhibitorer (PDE5) og anvendelser derav. NO20071446L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60446204P 2004-08-26 2004-08-26
US11/211,099 US20060205733A1 (en) 2004-08-26 2005-08-25 Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
PCT/US2005/030342 WO2006026395A1 (en) 2004-08-26 2005-08-26 Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof

Publications (1)

Publication Number Publication Date
NO20071446L true NO20071446L (no) 2007-03-26

Family

ID=36000390

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071446A NO20071446L (no) 2004-08-26 2007-03-16 Endotelin A reseptor (ETA)-antagonister i kombinasjon med fosfodiesterase 5-inhibitorer (PDE5) og anvendelser derav.

Country Status (12)

Country Link
US (1) US20060205733A1 (no)
EP (1) EP1789051A4 (no)
JP (1) JP2008510830A (no)
KR (1) KR20070074552A (no)
AU (1) AU2005280077A1 (no)
BR (1) BRPI0514666A (no)
CA (1) CA2578044A1 (no)
IL (1) IL181513A0 (no)
MX (1) MX2007002311A (no)
NO (1) NO20071446L (no)
RU (1) RU2007110933A (no)
WO (1) WO2006026395A1 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778252A4 (en) 2004-08-11 2010-01-27 Williamsburg Holdings Llc NON-CARDIOTOXIC PHARMACEUTICAL COMPOUNDS
CN101102775A (zh) * 2004-11-18 2008-01-09 先灵公司 采用pdev抑制剂治疗充血性心衰的方法
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
WO2007002125A1 (en) * 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
RU2412941C2 (ru) * 2006-03-13 2011-02-27 Инсайсив Фармасьютикалз, Инк. Полиморфы натриевой соли n-(4-хлор-3-метил-5-изоксазолил)-2[2-метил-4,5-(метилендиокси)фенилацетил]тиофен-3-сульфонамида
WO2007106494A2 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of diastolic heart failure
EP2001446A2 (en) * 2006-03-13 2008-12-17 Encysive Pharmaceuticals, Inc Formulations of sitaxsentan sodium
CA2652345A1 (en) * 2006-05-15 2007-11-22 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea related applications
FR2902009B1 (fr) * 2006-06-13 2012-12-07 Bioprojet Soc Civ Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire
WO2007146900A2 (en) * 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
EP2101777B1 (en) * 2006-12-12 2015-05-20 Gilead Sciences, Inc. Composition for treating a pulmonary hypertension
WO2008088727A2 (en) 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
CA2676066C (en) 2007-01-22 2016-06-28 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US20090004268A1 (en) * 2007-03-13 2009-01-01 Given Bruce D Methods and Compositions for Treatment of an Interstitial Lung Disease
JP5576790B2 (ja) * 2007-06-11 2014-08-20 アール ロッチ マクドナルド 脳血管れん縮の予防用薬物送達システム
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
AU2013203192B2 (en) * 2007-06-11 2015-12-24 Edge Therapeutics Inc. A drug delivery system for the prevention of cerebral vasospasm
CA2698786A1 (en) * 2007-09-11 2009-03-19 Dorian Bevec Use of a peptide as a therapeutic agent
CN101891747B (zh) * 2010-07-02 2012-04-25 张南 抑制5型磷酸二酯酶的化合物及制备方法
KR20130069855A (ko) 2010-10-15 2013-06-26 길리애드 사이언시즈, 인코포레이티드 폐 고혈압 치료의 조성물 및 방법
AU2012240131B2 (en) 2011-04-05 2017-07-20 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
EP2810943B1 (en) * 2012-01-31 2017-09-27 Eisai R&D Management Co., Ltd. Sitaxentan derivative
US9399019B2 (en) 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
CN105324395A (zh) * 2013-03-08 2016-02-10 艾伯维公司 治疗急性肾损伤的方法
CN110087653A (zh) * 2016-10-27 2019-08-02 普尔莫凯恩股份有限公司 用于治疗肺高血压的组合疗法
KR102896033B1 (ko) * 2022-12-22 2025-12-04 연세대학교 산학협력단 N-벤질퀴나졸린-4-아민 화합물을 포함하는, 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
MXPA00003997A (es) * 1999-04-30 2002-03-08 Lilly Icos Llc Articulos de fabricacion.
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
CN1489467A (zh) * 2001-02-02 2004-04-14 Ĭ��ר���ɷ����޹�˾ 含吡唑并[4,3-d]嘧啶和内皮素受体拮抗剂或者噻吩并嘧啶和内皮素受体拮抗剂的药物制剂
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination

Also Published As

Publication number Publication date
EP1789051A1 (en) 2007-05-30
RU2007110933A (ru) 2008-10-10
IL181513A0 (en) 2007-07-04
AU2005280077A1 (en) 2006-03-09
CA2578044A1 (en) 2006-03-09
US20060205733A1 (en) 2006-09-14
MX2007002311A (es) 2008-03-10
KR20070074552A (ko) 2007-07-12
JP2008510830A (ja) 2008-04-10
BRPI0514666A (pt) 2008-06-17
EP1789051A4 (en) 2009-10-21
WO2006026395A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
NO20071446L (no) Endotelin A reseptor (ETA)-antagonister i kombinasjon med fosfodiesterase 5-inhibitorer (PDE5) og anvendelser derav.
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
NO20072322L (no) Laktamforbindelser og anvendelse derav som farmasoytiske midler
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
NO20081569L (no) Administrasjon av dipeptidylpeptildaseinhibitorer
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20081592L (no) Dipeptidylpeptidaseinhibitorer for behandling av diabetes
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NO20070372L (no) Amidoforbindelser og anvendelse derav som farmasoytiske preparater
WO2005030187A3 (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
WO2005039485A3 (en) Gsk-3 inhibitors and uses thereof
NO20072599L (no) Inhibitorer av 11-beta-hydroksyl steroid dehydrogenase Type 1 og fremgangsmater for anvendelse derav
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
NO20010743L (no) Antivirale indoloksoacetyl-piperazin-derivater
NO20065442L (no) Amidoforbindelser og deres anvendelse som legemidler
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
NO20070334L (no) 4,6-disubstituerte pyrimidiner og deres anvendelse som proteinkinaseinhibitorer
NO20050514L (no) Sammensetning og antiviral aktivitet til substituerte azaindoloksoeddikpiperazinderivater
NO20075662L (no) Roflumilast for behandlingen av pulmonal hypertensjon

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application